Study to evaluate the impact of reactogenicity on Quality of Life (QoL), after administration of GlaxoSmithKline (GSK) Biologicals’ candidate Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) in adults ≥ 50 years of age

Trial Identifier: 204928
Sponsor: GlaxoSmithKline
NCTID:: NCT02979639
Start Date: January 2017
Primary Completion Date: April 2017
Condition: Other - Conditions

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, California Oakland, California, United States, 94612
United States, Colorado Aurora, Colorado, United States, 80045
United States, Colorado Colorado Springs, Colorado, United States, 80906
United States, Colorado Colorado Springs, Colorado, United States, 80922
United States, Idaho Meridian, Idaho, United States, 83646
United States, Missouri Kansas City, Missouri, United States, 64114
United States, North Carolina Durham, North Carolina, United States, 27705
United States, Oregon Corvallis, Oregon, United States, 97330
United States, Pennsylvania Uniontown, Pennsylvania, United States, 15401
United States, South Carolina Spartanburg, South Carolina, United States, 29303
United States, Virginia Norfolk, Virginia, United States, 23507